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SADS is defined as sudden death under the age of 40 years old in the absence of
structural heart disease. Family screening studies are able to identify a cause in up to
50% of cases-most commonly long QT syndrome (LQTS), Brugada and early repolarization
syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT) using
standard clinical screening investigations including pharmacological challenge testing.
These diagnoses may be supported by genetic testing which can aid cascade screening
and may help guide management. In the current era it is possible to undertake molecular
autopsy provided suitable samples of DNA can be obtained from the proband. With the
evolution of rapid sequencing techniques it is possible to sequence the whole exome for
candidate genes. This major advance offers the opportunity to identify novel causes of
lethal arrhythmia but also poses the challenge of managing the volume of data generated
and evaluating variants of unknown significance (VUS). The emergence of induced
pluripotent stem cell technology could enable evaluation of the electrophysiological
relevance of specific ion channel mutations in the proband or their relatives and will
potentially enable screening of idiopathic ventricular fibrillation survivors combining
genetic and electrophysiological studies in derived myocytes. This also could facilitate
the assessment of personalized preventative pharmacological therapies. This review will
evaluate the current screening strategies in SADS families, the role of molecular autopsy
and genetic testing and the potential applications of molecular and cellular diagnostic
strategies on the horizon.
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INTRODUCTION
Of the 484,367 deaths registered in England and Wales in
2011, 29% were attributed to circulatory disorders (Births and
Deaths in England and Wales, 2011). A report in 2009 found
that sudden cardiac death was responsible for ∼60,000 deaths,
with ischemic heart disease the major cause (Papadakis et al.,
2009). In the younger population (1–35 years of age), sudden
cardiac death is the most common cause of premature death
(Tester and and Ackerman, 2012). Here, a thorough investi-
gation including autopsy is critical in identifying a cause—for
instance, structural abnormalities such as cardiomyopathies [e.g.,
hypertrophic cardiomyopathy (HCM)] may be identified at the
point of autopsy. However, in a substantial proportion (reports
ranging from 3–53% Tester and and Ackerman, 2012) despite
extensive post-mortem examination, no structural cause of death
may be identified. It is thought that ion channelopathies such
as Long QT Syndrome (LQTS) may explain a significant num-
ber of these events. Cases of sudden death in patients between
the ages of 1–40 years with no previous cardiac history, who are
seen alive in the 12 hours preceding death and have a normal
coroner’s autopsy (confirmation of a normal heart by an expert
cardiac pathologist) in addition to a negative toxicological screen
are deemed to have sudden arrhythmic death syndrome (SADS;
Nunn and Lambiase, 2011). It is this syndrome that will form the
focus of the review.
EPIDEMIOLOGY
SADS is thought to be responsible for an estimated 0.24
deaths per 100,000 population according to an analysis of death
certification data from England and Wales (Papadakis et al.,
2009). This contrasts strongly with data available from north-
east Thailand where it has been demonstrated that amongst
men aged 20–49, the annual incidence of sudden unexplained
death is 38 per 100,000 population per year (Tungsanga and
Sriboonlue, 1993), with Brugada syndrome (BrS) thought to be
the main cause for this dramatically higher rate of sudden death
(Sangwatanaroj et al., 2001). Cardiac ion channelopathies such as
LQTS, BrS, Catecholaminergic polymorphic ventricular tachycar-
dia (CPVT) cannot be identified on conventional autopsy while
certain cardiomyopathies including arrhythmogenic right ven-
tricular cardiomyopathy (ARVC) and HCM may be missed at
post-mortem due to subtle histological anomalies. The yield of
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genetic screening varies considerably according to the syndrome
in question—some forms of LQTS e.g., Timothy Syndrome have
a diagnostic yield that is near 100% while in ARVC, for instance,
only 30–40% of clinically diagnosed patients have desmoso-
mal mutations which are thought to be the main cause of the
condition (Priori and Napolitano, 2006).
ION CHANNELOPATHIES ASSOCIATED WITH A
STRUCTURALLY NORMAL HEART
The inherited arrhythmia syndromes LQTS, CPVT, and BrS form
a substantial proportion of fatal arrhythmia-associated sudden
deaths on the background of a structurally normal heart. Here,
the epidemiology, genetic basis of the syndromes, the characteris-
tic clinical features as well as insights into how genotype may play
a role in guiding management and prognosis will be discussed (a
list of known genes involved in the various syndromes is outlined
in Table 1).
Table 1 | Genetic basis of principal ion channelopathies [adapted from
Table 1, Giudicessi and Ackerman (2013)].
Gene Protein Frequency
LQTS
KCNQ1 (LQT1) Kv7.1 30–35%
KCNH2 (LQT2) Kv11.1 25–30%
SCN5A (LQT3) Nav1.5 5–10%
ANKB (LQT4) Ankyrin B <1%
KCNE1 (LQT5) MinK <1%
KCNE2 (LQT6) MiRP1 <1%
KCNJ2 (LQT7) Kir2.1 <1%
CACNA1C (LQT8) Cav1.2 <1%
CAV3 (LQT9) Caveolin 3 <1%
SCN4B (LQT10) Nav1.5 β4-subunit <1%
AKAP9 (LQT11) Yotiao <1%
SNTA1 (LQT12) Syntrophin- α1 <1%
KCNJ5 (LQT13) Kir3.4 <1%
CPVT
RYR2 (CPVT1) Ryanodine receptor 2 50-60%
CASQ2 (CPVT2) Calsequestrin 2 1–2%
KCNJ2 (CPVT3) Kir2.1 10%
BrS
SCN5A (BrS1) Nav1.5 20–30%
GPD1L (BrS2) Glycerol-3-phosphate
dehydrogenase 1-like
<1%
CACNA1C (BrS3) Cav1.2 6.6%
CACNB2 (BrS4) Cav1.2 β2-subunit <1%
SCN1B (BrS5) Nav1.5 β1-subunit <1%
KCNE3 (BrS6) MiRP2 <1%
SCN3B (BrS7) Nav1.5 β3-subunit <1%
KCNJ8 (BrS8) Kir6.1 2%
CACNA2D1 (BrS9) Cav1.2 α2/∂1-subunit <1%
KCND3 (BrS10) Kv4.3 <1%
MOG1 (BrS11) Mog1 <1%
Note the likely syndrome subtype recorded in parenthesis but no consensus on
numerical nomenclature for minor syndrome subtypes.
LONG QT SYNDROME
LQTS is defined by delayed repolarization of the myocardium.
Clinically, this corresponds to a prolonged heart rate-corrected
QT interval (QTc). Such patients have an increased risk of syn-
cope, seizures, and sudden death. Its incidence is thought be
1/2000 (Schwartz et al., 2009) and so far 13 LQTS-associated
genes have been implicated in this disorder. However, 60–75% of
patients with definite LQTS have mutations in one of the three
major susceptibility genes (Giudicessi and Ackerman, 2013). The
remaining 10 genes are thought to increase the yield by less than
5% and contribute to an increase in false positives (Giudicessi and
Ackerman, 2013). Triggers associated with LQTS include exer-
tion, swimming, emotion, auditory stimuli e.g., alarm ringing
with such triggers potentially bringing about syncope, seizures
and in 5% untreated cases sudden fatal arrhythmia (Lambiase,
2010). Table 2 summarizes (Ackerman et al., 2011; Gollob et al.,
2011; Tester and and Ackerman, 2012; Giudicessi and Ackerman,
2013) the key features of the three principle LQTS syndromes and
Figure 1 illustrates some typical ECG patterns.
Current management guidelines of the Heart Rhythm
Society/European Heart Rhythm Association (Ackerman et al.,
2011) state that comprehensive/targeted LQTS genetic testing is
recommended for anyone where there is strong evidence to sug-
gest LQTS based on the phenotype (history, family history, ECG
findings). For relatives of the index patient, mutation-specific
testing is recommended even if they are asymptomatic with a
normal ECG. Genotyping has been helpful in directing therapy:
for instance β-blockade has been shown to have similar effects
in preventing cardiac events in LQT1 and LQT2 patients but not
having the same degree of beneficial effect in LQT3 (Moss et al.,
2000).
BRUGADA AND EARLY REPOLARIZATION (“J WAVE”) SYNDROME
BrS is characterized by coved-type ST-segment elevation followed
by a negative T-wave in right precordial leads V1–V3 (type 1
ECG pattern) or saddleback pattern in V1 (with ST-segment ele-
vation) or V2 (without ST-segment elevation). However, only a
type 1 pattern is diagnostic of the syndrome where there is ST-
segment elevation in >1 precordial lead (standard/high position
V1–V3) in the presence/absence of a sodium channel blocker
(see Figures 2, 3) in addition to either documented ventricular
fibrillation (VF), polymorphic VT, family history of sudden car-
diac death aged <45 years, coved-type ECG changes in family
members, inducibility of VT with programmed electrical stim-
ulation, syncope, or nocturnal agonal respiration (Haïssaguerre
et al., 2008). The estimated prevalence is 1/2000 in Caucasians
although the prevalence may be more in individuals of Asian
descent (Antzelevitch et al., 2005). So far, mutations in at least
11 distinct susceptibility genes have been identified. The most
common being mutations in the SCN5A gene (20–30% cases),
while the other 10 genotypes identified so far are comparatively
much rarer and thus only in BrS type 1 is gene testing for SCN5A
mutations thought to be clinically useful at present, when there
is a strong clinical suspicion of BrS based on clinical data (his-
tory, family history and ECG findings; Ackerman et al., 2011;
Gollob et al., 2011). Cascade screening of relatives of the proband
can follow thereafter. Patients are characteristically young males
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Table 2 | Outline of the current genetic testing recommendations for the principal ion channelopathies.
Likely arrhythmia
syndrome
Prevalence Major clinical
triggers
Characteristic ECG
findings
Exercise testing Pharmacological
challenge testing
Recommended
genetic testing
LQT1 Overall
LQTS
1/2000
Exercise Broad tented T wave QTc fails to shorten
particularly in the
recovery phase of
exercise
IV epinephrine
prolongs QTc
(epinephrine could
be helpful in
unmasking LQTS
and thus identifying
new pathogenic
mutations where the
QTc is normal at
rest)
KCNQ1, KCNH2, and
SCN5A.
Routine clinical
testing of rare genes
(<1% detection rate)
not recommended. If
patients have a clear
clinical phenotype
but negative in
genetic testing for
the above genes,
rare genes may be
assessed on a
case-by-case basis.
LQT2 Emotional stimuli Bifid T wave
LQT3 Sleep and rest
without arousal
Late onset
peaked/biphasic T
wave
Prolongation of QTc
at night (24 hour
ECG thus of great
importance)
BrS 1/2000 Rest or sleep Coved-type
ST-segment elevation
in right precordial
leads (type 1 ECG
pattern)
IV sodium channel
blocker converting a
type 2 or type 3 ECG
pattern to a type 1
ECG pattern
SCN5A gene testing
only.
CPVT 1/7000–
10,000
Emotion/Exercise
(high adrenaline
states)
Baseline usually
normal
Bidirectional
VT/polymorphic VT
IV infusion of
adrenergic agonist
inducing bidirectional
VT/polymorphic VT
RYR2 gene; if RYR2
gene screening
negative despite high
clinical suspicion
then consider
CASQ2 screening.
aged about 40 when the arrhythmias first manifest, with sleep
being a major trigger (Antzelevitch et al., 2005). However, the
majority of families screened have normal or borderline/subtle
changes in the J point. Hence, pharmacological challenge testing
using a sodium channel blocker is key in unmasking the condition
(Figure 3).
Until recently inducibility of VT at electrophysiological study
was thought to be predictive of sudden death risk (Priori et al.,
2002a). However, recent large series have shown that this is not
consistent, meaning it has dropped to a class IIb level of evidence
in the recent HRS/EHRA Consensus Statement on the assess-
ment of ion channel disorders (Eckardt et al., 2002; Tester and
Ackerman, 2011; Priori et al., 2012). Other parameters such as
ventricular effective refractory period, signal averaged ECG and
ST changes in recovery may play a role in the future.
Currently, as per the HRS/EHRA guidelines, only SCN5A
genetic testing is useful when there is strong clinical/ECG data to
suggest BrS in the index case with a view to identifying a causative
mutation and thereby facilitating cascade screening of relatives.
However, as yet there is no clear therapeutic or prognostic utility
in genetic testing (Ackerman et al., 2011).
Recent attention has been focused on the potential arrhyth-
mogenic risk of J waves or early repolarization on the resting
12 lead ECG. Haïssaguerre et al. (2008) and Rosso et al. (2008)
have demonstrated a significantly higher prevalence of J point
elevation in the infero-lateral leads in idiopathic ventricular
fibrillation survivors vs. matched healthy controls, coupled with
pronounced J point elevation preceding the development of VF.
The precise mechanism of this early repolarization phenomenon
in humans remains uncertain. Recently, a Finnish population
study of over 10,000 unselected people with a mean follow up
of 30 years found that the presence of J point elevation was
associated with a higher rate of death from cardiac causes and
arrhythmia (Tikkanen et al., 2009) further supporting the notion
that J point elevation may indicate an increased susceptibility
to lethal arrhythmia, acting as a modifying factor whatever the
underlying pathology. Our group has identified a higher propor-
tion of SADS relatives with J waves vs. the general population,
this suggests that the heritable J point elevation could account for
a proportion of SADS deaths caused by ion channel mutations in
the KATP channel and L-type Calcium channel (Antzelevitch and
Yan, 2010; Nunn et al., 2011).
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR
TACHYCARDIA (CPVT)
CPVT is a disease of perturbed intracellular calcium homeosta-
sis. Like LQTS, it is associated with a structurally normal heart
however it usually displays a completely unremarkable resting
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FIGURE 1 | Examples of ECGs for different forms of Long QT Syndrome
(A). Long QT 1 (B) LQT2 illustrating bifid T wave morphology (C). Long QT3
illustrating flat isoelectric segment with small symmetrical T wave
particularly in lead III.
ECG (occasionally bradycardia and U waves) and is usually
only unmasked (ventricular ectopy is seen) following exertion
or catecholaminergic stress testing (Tester and Ackerman, 2011)
(Figure 4). It is thought to affect 1/7000–10,000 individuals with
three distinct CPVT-associated genes so far identified (Giudicessi
and Ackerman, 2013). Sixty to sixty-five percent of CPVT cases
are associated with a mutation in the RYR2-encoded cardiac
ryanodine receptor/intracellular calcium channel—CPVT type 1
(CPVT1; Priori et al., 2002b). The remainder of the mutations
in the other two susceptibility genes are found in fewer than
5% cases (Crotti et al., 2012). A rare autosomal recessive form
of CPVT has been associated with mutations in calsequestrin
(CASQ2; Lahat et al., 2001). Both CASQ2 and RYR2 encode
proteins involved in intracellular calcium handling. Mutations
may predispose to elevated calcium levels during cardiac diastole
and thus increasing the risk of developing ventricular arrhyth-
mias. Genetic testing is currently recommended for anyone
where clinical features and ECG findings observed on exer-
cise/catecholaminergic testing indicate CPVT (Ackerman et al.,
2011). This of course facilitates mutation-specific cascade screen-
ing of family members and advice on avoidance of triggers
i.e., exercise. Genotype however does not impact on manage-
ment or risk stratification strategies at present (Eckardt et al.,
2002), although there is some evidence to indicate prophylactic
β-blockade in these individuals may be useful.
SHORT QT SYNDROME
This arrhythmia syndrome is comparatively infrequently encoun-
tered in clinical practice. It is however associated with a high inci-
dence of syncope and sudden cardiac death, even in the younger
patients and newborns. The defining electrocardiographic fea-
ture is QTc < 320ms. Mutations in KCNH2, KCNQ1, and KCNJ2
genes have been identified as associated with the condition.
However, data is limited on the condition (a recent population
screening study over 100,000 ECGs failed to identify a single case)
and very little evidence is available to help guide genetic screening
of this condition (Lambiase, 2010).
Having briefly overviewed the various arrhythmia syndromes,
it is evident that a clinical diagnostic approach must first be fol-
lowed in these scenarios and then targeted genetic screening if
a clear phenotype is identified to maximize the yield of genetic
screening in the family.
SCREENING
THE CLINICAL SCREENING APPROACH TO SADS FAMILIES
Screening of the 1st degree relatives in specialist clinics can
diagnose an inherited cardiac condition in 22–53% of fami-
lies. Behr et al. (2003) investigated 109 1st degree relatives of
32 people who died of SADS. Seven (22%) of the 32 families
were diagnosed with an inherited cardiac disease. A subsequent
more detailed evaluation of 57 consecutively referred families
with SADS death identified 30 families (53%) with an inheri-
table heart disease (Giudicessi and Ackerman, 2013). Over half
of those relatives affected received potentially lifesaving inter-
vention with β-blockers and/or an ICD (Behr et al., 2008). Tan
et al. (2005) investigated 43 consecutive families with >1 SADS
victim who died at <40 years of age. Only 51% of probands
underwent a post-mortem. 183 relatives were initially screened
triggering the cascade screening of a further 150 relatives. A diag-
nosis was established in 17 of 43 families (40%) and revealed
151 pre-symptomatic disease carriers. Most recently, Wilde and
colleagues (Van Der Werf et al., 2010) reported the assessment
of 140 families with a sudden unexplained death (aged 1–50
years.) A diagnosis was established in 33% of families although
a post mortem was performed in only 46% of cases. Strategies
to increase the diagnostic yield include: ensuring all cases have a
post-mortem, ideally with an expert cardiac pathologist review of
the whole heart; reviewing as many 1st degree relatives in each
family as possible; and carrying out a molecular autopsy where
possible.
PRACTICAL CONSIDERATIONS OF CLINICAL SCREENING
Effective clinical screening of SADS families requires a compre-
hensive multidisciplinary team approach. Moreover, chapter 8
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FIGURE 2 | A typical Brugada syndrome type 1 ECG showing coved ST elevation in leads V1 and V2.
FIGURE 3 | Pharmacological challenge testing unmasking in Brugada
phenotype. Type 1 response to ajmaline challenge test.
of the National Service Framework in the UK requires the
National Health Service (NHS) to provide a dedicated clinic
to assess families with appropriately trained staff (Department
of Health, 2005). A dedicated clinic typically comprises car-
diologists, physiologists, echocardiographers, specialist nurses,
bereavement and genetic counselors, and clinical geneticists
(Lambiase, 2010).
Prior to seeing families in a SADS clinic, as much background
information as possible should be obtained about the index case.
This should include specific clinical information such as previous
FIGURE 4 | Bidirectional VT in CPVT.
clinical encounters with a family physician or visits to the emer-
gency department, as this may yield useful diagnostic information
such as previous ECGs. Additionally, a detailed post-mortem
report should be obtained. Usually a specialist nurse will coor-
dinate the clinic and liaise with families, the family physician as
well as the coroner’s office to obtain relevant background infor-
mation including a copy of the post-mortem report. Moreover,
tissue sections or ideally the whole heart should be reviewed by
a specialist cardiac pathologist to identify any histopathological
evidence of an underlying cardiomyopathic process. For instance,
myocyte disarray suggestive of HCM or local fibrosis and fatty
infiltration indicative of ARVC may be identified (Lambiase,
2010).
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Importantly, prior to conducting any investigations on SADS
families, appropriate counseling must be undertaken to ensure
the implications of the screening tests are well-understood.
Employment, insurance, effects on children and other family
members as well as the psychological impact of test results
must all be appropriately discussed. The outcomes of investiga-
tions can vary from inconclusive non-diagnostic findings, which
require regular follow-up to the need for medical therapy (e.g.,
β-blockers) or even invasive procedures such as the insertion of
an implantable cardioverter-defibrillator (ICD) device (Lambiase,
2010).
CONSULTATIONWITH PHYSICIAN
HISTORY
Family screening should start with a detailed evaluation of the
index case. The mode of death may provide useful information
regarding etiology. For instance, long QT (LQT) 1 subtype
(LQT1) and catecholaminergic polymorphic VT is associated
with death while swimming (Tester and Ackerman, 2011).
Syncope in the context of sudden loud noise or alarm is character-
istic of LQT2 and death during sleep suggests the possibility of BrS
and LQT3 (all three associated with an increased risk of arrhyth-
mia during periods of increased cholinergic tone or bradycardia).
Thus, a careful and systematic history from first-degree rela-
tives can be great value in helping to determine the details prior
to pre-syncopal or syncopal events as well as identifying other
symptomatic family members.
Past medical history, previous accidents, prescribed/non-
prescribed and recreational drugs e.g., cocaine use are all of
relevance. Family history including any relatives who may have
died under 40 years of age, family history of cardiac interven-
tions e.g., pacemaker implantation, heart failure or any available
death certification can all be invaluable. Certain markers in the
history including syncope, 2 or more sudden deaths in the fam-
ily at younger (≤40 years) age are all thought to be predictive
markers of a diagnosis in the family (Tan et al., 2005; Behr et al.,
2008).
INVESTIGATIONS
A number of tests may be performed to aid in the screening pro-
cess of SADS families. These will be at the physician’s discretion
and may vary between units. These can include a resting ECG,
exercise ECG, VO2 max tests, signal averaged ECG, transtho-
racic echocardiogram and ajmaline or flecainide challenge test (to
unmask BrS when suspected; Lambiase, 2010).
THE ROLE OF GENETIC TESTING
There has been a steady advance in the potential for gene
testing since the discovery of the channelopathy-causing genes
in the 1990s. With an ever-burgeoning panel of commercially
available diagnostic genetic tests available to the electrophysiol-
ogist, consensus guidance is clearly highly relevant in helping
to determine when and which tests are indicated. The Heart
Rhythm Society/European Heart Rhythm Association Consensus
Statement published in 2011 (Ackerman et al., 2011) aptly
summarizes the current recommendations for genetic screen-
ing. These have been outlined together with overviews of the
principal genetic syndromes associated with SADS in the sum-
mary table [Ackerman et al., 2011; Gollob et al., 2011; Tester
and and Ackerman, 2012; Giudicessi and Ackerman, 2013; above
(Table 2)].
PRACTICAL CONSIDERATIONS OF GENETIC TESTING
Genetic testing is usually employed as a confirmatory tool pri-
marily to facilitate cascade screening of the family. Only after
a thorough clinical assessment (with likely diagnosis established
based on family history, patient background, ECG and pharmaco-
logical testing) should genetic screening be used in clinical prac-
tice. Moreover, genetic counseling (to include a comprehensive
discussion of the relative risks and benefits) is highly recom-
mended prior to any testing (Ackerman et al., 2011). The benefits
offered by testing are in identifying a specific genetic mutation,
which may help, to determine both management and prognosis
of affected family members, best illustrated in the case of LQTS
(see below). Alternatively, where the clinical screening process
does not yield sufficient information to make a diagnosis or may
require a large number of first-degree relatives to be screened, a
single genetic test may prove to be themost cost-effective method.
Furthermore, genetic testing may assist in family planning or for
prenatal diagnosis in a parent who carries a known mutation
(Schwartz et al., 2009). However, the yield of genetic testing varies
considerably among the channelopathies; from 20% in BrS to
75% for LQTS (Ackerman et al., 2011). Hence, a negative test does
not rule out the presence of a particular disease. Furthermore,
the diagnostic, therapeutic and prognostic benefit derived from
a genetic test is also highly disease-specific. Hence, testing must
always be considered in the context of relevant clinical data
(Ackerman et al., 2011).
CLINICAL IMPACT OF GENETIC TESTING
Out of the channelopathies, LQTS testing has the highest yield as
well as the maximum evidence for being able to guide diagnosis
and management (Ackerman et al., 2011). Hence, this syndrome
is well-placed to illustrate the clinical impact of genetic testing.
Testing for theKCNQ1, KCNH2, and SCN5A genes, when LQTS is
clinically suspected, should yield positive LQT1-3 causing muta-
tions in 75% cases (Ackerman et al., 2011). However, as alluded
to earlier negative testing does not exclude the disease where there
is strong clinical suspicion. On the other hand, testing should
not be performed without clinical suspicion, considering there
is a substantial rate of rare variants of unknown significance
(VUS) i.e., where there is insufficient evidence to label muta-
tions as definitely disease-causing (discussed in detail later)—
4–8% in the LQT1-3 genes (Kapa et al., 2009). Identifying a
causative mutation in an index case of LQTS mandates mutation-
specific cascade screening of all first-degree relatives (even when
there is no clinical suspicion in that relative). Helpfully, in the
absence of a clinical phenotype for LQTS in the relative, a neg-
ative genetic test will effectively exclude LQTS (Ackerman et al.,
2011).
Genetic testing can additionally direct therapy in LQTS: β-
blockers are highly protective in the case of LQT1 patients,
moderately protective in LQT2 (Runa et al., 2008) while in
LQT3 other agents such as mexiletine, flecainide, ranolazine, or
Frontiers in Physiology | Cardiac Electrophysiology September 2013 | Volume 4 | Article 199 | 6
Vyas and Lambiase Investigation of sudden arrhythmic death syndrome (SADS)
propranolol are indicated (Schwartz et al., 1998; Moss et al.,
2005, 2008; Ackerman et al., 2011). Hence, gene-directed thera-
peutic options are highly significant here. Prognostically, geno-
type appears also to be very significant: for instance, LQT1
transmembrane-localizing missense mutations have a greater risk
of an LQT1-triggered cardiac event compared to a C-terminal
mutation (Shimizu et al., 2004). In LQT2, patients with pore-
region mutations tend to have longer QTc and more severe
clinical manifestations (Moss et al., 2002). For the other prin-
cipal channelopathies—CPVT and BrS, while cascade screening
of index cases is indicated, there is no clear genotype-dependent
differential therapeutic approach nor does genotype influence
prognosis as yet (Ackerman et al., 2011).
In summary, genetic testing serves a vital role in confirmatory
testing of individuals with a robust clinical phenotype and facili-
tates cascade family screening of index cases. However, at present,
it is only in LQTS that genotype helps to clearly direct therapy and
inform prognosis.
MOLECULAR AUTOPSY: THE NEW FRONTIER
Molecular autopsy refers to the use of DNA extracted from tissue
retained after the post-mortem, which can be utilized for confir-
matory testing of a mutation identified in the relative (Lambiase,
2010). This approach facilitates post-mortem genetic testing of
conditions that are known to cause SADS e.g., LQTS. The first
reported case of the use of molecular autopsy to diagnose an
inherited arrhythmia syndrome was by Ackerman et al. (1999).
They found a 9 base pair deletion in the KVLQT1 gene of a 19
year-old, previously fit and well lady, who had died after being
resuscitated following a near-drowning experience. Subsequently,
this same mutation had been found in the proband’s other family
members and appropriate therapy was then offered to the affected
family members.
Only a handful of molecular autopsy series have been reported
to date with one of the largest reported by Tester et al. (2012)
who performed a comprehensive mutational analysis in 173
cases of the LQTS susceptibility genes as well a targeted analy-
sis of the CPVT type 1-associated RYR2 gene. Forty-five puta-
tive pathogenic mutations (25 novel mutations) were identified
(26.0% yield). Correlation of genotype with phenotype demon-
strated that females showing a higher yield than males (38.8 vs.
17.9%) andmutation-positive females were more likely to host an
LQTS-associated mutation while mutation-positive males more
likely to host a CPVT1-associated mutation. Exertion (34.8%)
and sleep (18.6%) were also major triggers. Furthermore, 40.5%
of cases (70/173) were found have a positive personal or fam-
ily history of syncope, seizures, cardiac arrest, near drowning, or
unexplained drowning (in a family member) or a known pro-
longed QT interval. This builds on their earlier study of 49 cases
(Tester and Ackerman, 2007). Data from a series in Denmark
(Larsen et al., 2013) found that in the 0–40 year old popula-
tion, there was a yield of 8.3% in targeted RYR2 gene sequencing.
This follows-up from earlier series including that by Chugh et al.
(2004), who showed in a cohort of 270 sudden death cases over
a 13 year period that there were 12 autopsy negative cases of
which 2 showed a mutation in the KCNH2 gene. More recently,
Skinner et al. (2011) found that in a prospective population-based
long QTmolecular autopsy study of 1–40 year-olds, 5/33 had rare
possible LQTS-associated mutations.
PRACTICAL CONSIDERATIONS
In most autopsy studies, DNA extraction is typically based on
formalin-fixed, paraffin-embedded tissue (FF-PET) due to the
comparative ease of storing and transporting tissue (Basso et al.,
2010). However, DNA extracted from this source is thought to be
unreliable for molecular autopsy and usually inadequate for com-
prehensive post-mortem genetic testing (to detect a pathological
mutation; Carturan et al., 2008). Indeed, a study by Doolan et al.
(2008) found no putative pathogenic mutations in a series of 59
cases of sudden expected death when using DNA extracted from
FF-PET. Optimal sources of intact DNA include blood collected
in ethylenediaminetetraacetic acid (EDTA) or frozen heart, liver,
or spleen tissue. Furthermore, 10–15ml of EDTA blood or 5–10 g
of fresh tissue should be obtained at autopsy and stored at −80◦C
to provide the ideal source of material for comprehensive genetic
testing (Ackerman et al., 2001). In order to try and combat the
limitations of material for autopsy, Gladding et al. (2010) used
DNA extracted fromGuthrie blood spots and used whole genome
amplification prior to sequencing. They found out of 19 cases in
their series, 4 had pathological mutations and all probands had
at least one first-degree family member with the same mutation.
This was followed-up by a Danish group (Winkel et al., 2012)
who showed a yield of 11% for 3 major LQTS-associated genes
amongst a cohort of 1–35 year-olds.
The advent of full exonic sequencing will mean that the whole
patient exome can be sequenced. This significantly reduces the
cost of gene testing but also generates enormous quantities of
bioinformatic data with multiple genetic variants and potentially
mutations in other non-cardiac genes being identified. At present,
we only have a limited understanding of the etiology of recog-
nized arrhythmic conditions. Hence, the interpretation of any
additional genetic information must be carefully assessed and
put into the context of the patient/family being screened. This is
particularly important considering we are currently severely ham-
pered by our limited ability to assess the pathogenicity of specific
variants.
RECOMMENDATIONS
Most of the series published so far are a relatively small in size.
Thus, larger studies and analyses are required to help better char-
acterize the yield of mutation detection and also offer better
phenotype/genotype correlations. For instance, helping to iden-
tify clinical correlations between genetic mutations and clinical
characteristics such as age or gender. This would contribute to
guiding the clinical evaluation of the proband’s family members
and improving the cost effectiveness of the current approach.
At present a combined clinical diagnostic approach and molec-
ular autopsy would be recommended, as mutation carriers may
only have minor manifestations of disease and compound het-
erozygotes may have clinically milder or more severe forms of the
condition depending upon the functionality of the complemen-
tary allele gene. For example, if the complementary gene is itself
a polymorphism with a down-regulation in function to 30%, this
cannot compensate for the effects of a non-functioning channel
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and hence significantly reduces repolarization reserve in the case
of LQTS (Crotti et al., 2005).
VARIANTS OF UNKNOWN SIGNIFICANCE
Another major question looms regarding VUS identified on gene
testing. As briefly mentioned earlier, VUS refer to mutations
where there is inadequate evidence to deem them as disease-
causing; increasingly, this is becoming an issue with the declin-
ing costs of genetic screening allowing large sections of the
genome or indeed the whole exome to be sequenced. Cotton and
Scriver (1998) have outlined several criteria that help determine
whether a mutation or variant is indeed a disease-causing muta-
tion (when taken in context of the other clinical data). These
include:
– non-sense/frameshift mutations leading to generation of stop
codons or downstream stop codons, respectively
– insertion/deletion mutations leading to truncated protein
products
– co-segregation of the variant with disease
– absence/rarity of the variant in control populations
– mutations in highly conserved amino acid residues/domains
likely altering the gene product
– functional analysis of the gene product through in vitro expres-
sion analysis
Satisfying any one of the criteria above does not necessarily
point toward a definitive designation as a pathogenic mutation.
Moreover, if taken together the criteria above do not allow for a
variant to be considered disease-causing, it is thereafter deemed
a VUS until further analysis (including functional assessment) is
used to confirm whether it is pathogenic. Moreover, the presence
of a VUS should not be used to assist in the diagnosis of an index
patient nor should it be used for cascade screening of relatives
(Giudicessi and Ackerman, 2013).
In light of recent genome-wide association studies (GWAS),
new insights have been gained into potential variants that may
be associated with increased risk of sudden cardiac death. Arking
et al. (2006) assessed the QT interval extremes in a cohort of
German subjects. They identified NOS1AP, a regulator of neu-
ronal nitric oxide synthase as a potential novel disease-causing
gene modulating cardiac repolarization with one minor allele
explaining up to 1.5% of QT interval variation. Further studies
specifically assessed the effect of NOS1AP variants in known ion
channelopathy populations. Crotti et al. (2009) assessed the clini-
cal manifestations and symptom occurrence in a South African
LQTS population (with a KCNQ1 mutation). They found that
LQTS individuals with the rs4657139 variant in NOS1AP had
greater probability of cardiac arrest and sudden death and had
a greater likelihood of having a more prolonged QT interval.
Taken together these findings would indicate that variants in the
NOS1AP gene could act as genetic modifiers with a potentially
significant impact on electrical function. Tomas et al. (2010) find-
ings supported the work of Crotti et al. (2009). They found in a
LQTS1 cohort with mutations in 5-associated genes that alleles
rs4657139 and rs16847548 were associated with an increased risk
of cardiac events. This would add further evidence to the notion
that specific variants in NOS1AP gene act as risk-modifiers in
known LQTS patients.
Albert et al. (2010) demonstrated in a case-control study of
6 prospective cohorts that 2 common intronic variants in the
KCNQ1 and SCN5A genes were significantly associated with sud-
den death in individuals of European descent (after adjustment
for cardiovascular risk factors). The alleles identified were the
T-allele at rs22832222 in KCNQ1 with a population frequency of
67 and 60% for the C-allele at rs11720523 in the SCN5A gene.
Finally, in the largest meta-analysis of GWAS to date, Arking
et al. (2011) found that there is a strong association with sudden
cardiac death at locus 2q24.2 including the BAZ2B gene, which is
thought to increase risk of sudden cardiac death by >1.9 fold per
allele in individuals of European descent.
While GWAS have opened an avenue to identifying novel VUS
which may indeed go on to be causative or risk-modifying due to
the impact on electrical function, caution must be exercised until
further functional studies are performed to identify the risk of
cardiac events. Hence, the presence of a VUS should not be used
to assist in the diagnosis of an index patient nor should it be used
for cascade screening of relatives at present and is therefore, as yet,
generally not a realistic screening tool (Giudicessi and Ackerman,
2013).
THE POTENTIAL ROLE OF INDUCED PLURIPOTENT STEM
CELL TECHNOLOGY IN FUNCTIONAL ION CHANNEL
MUTATION TESTING AND CLINICAL EVALUATION
Since human embryonic stem cells (hESCs) were first isolated
from blastocysts in 1998, it has become possible to produce
human-induced pluripotent stem cells (hiPSCs) by reprogram-
ming somatic cells with just four genetic factors (Thomson et al.,
1998; Takahashi et al., 2007; Yu et al., 2007). This means that
a skin biopsy can be taken from a patient or SADS index case
and fibroblasts cultured and reprogrammed to create specific cell
lines with cardiomyocytes being the most relevant in the context
of SADS.
These cells can be characterized by techniques including patch
clamping and multi-electrode array (MEA) to interrogate their
electrophysiological behavior (Terrenoire et al., 2013) (Figure 5).
Alterations in calcium handling can be visualized using real-time
microscopy utilizing calcium sensitive dyes (Jung et al., 2011).
There is now data from hiPSC lines carrying mutations that
cause LQTS and CPVT which shows these cells not only reca-
pitulate the clinical phenotypes but the response to drugs can
be reproduced in vitro (Figure 5) (Matsa et al., 2011). This has
an advantage over heterologous cell expression systems for test-
ing individual ion channel mutations using human embryonic
kidney (HEK) cells, and Chinese Hamster Ovary (CHO) cells
which lack the ion channels and cofactors that are relevant to
human cardiac electrophysiology. In the case of LQTS2, caused
by mutations in the IKr channel, hiPSC-derived cardiomyocytes
(hiPSC-CMs) developed arrhythmias when exposed to isopre-
naline, a stressor used clinically to precipitate and diagnose the
condition (Terrenoire et al., 2013). This effect could be reversed
by applying the patient’s own medication, nadolol (a β-blocker),
dantrolene and roscovitin; drugs known to be beneficial in mod-
erating calcium flux, stabilized ion flux in hiPSC models of the
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FIGURE 5 | Potential Uses of iPSC-CMs in the Investigation of SADS.
Derivation of cells (A) Immunostaining for cardiac troponin I (TrpI) and
a-actinin in myocytes derived from hESCs, HF–hiPSC, LQT2–hiPSC, and
MAT–hiPSC, showing characteristic cardiac muscle striations. (B)
Characterization of cellular electrophysiology: Image of an LQT2–hiPSC
beating cluster mounted onto a multi-electrode array for electrophysiology
analysis, and graph showing prolongation in QT interval and field potential
duration in LQT2–hiPSC beaters relative to controls. (From Matsa et al., 2011).
(C) Testing of drugs: (i) Averaged and (ii) raw action potential curves of
LQT2–hiPSC myocytes showing isoprenaline-induced arrhythmogenesis (blue
traces) and attenuation of this phenotype by nadolol (yellow trace) or
propranolol (green trace).
calcium channel disorders, CPVT and Timothy syndrome (linked
to LQT type 8), respectively (Matsa et al., 2011; Pasca et al., 2011;
Yazawa et al., 2011).
However, this approach still requires significant refinement as
there are a number of issues related to iPSC technology which
will affect its application to the evaluation of specific ion chan-
nel mutations. The utilization of this technology and its pitfalls
has been recently extensively reviewed in this journal (Hoekstra
et al., 2012). Mixed cultures of atrial and ventricular myocytes are
obtained affecting cellular electrophysiology and their response
to specific drugs. These selected populations of the derived cells
vary in their membrane potentials compared to other popula-
tions, which will affect the ion channel gating properties and
thereby alter the behavior of a specific mutant ion channel under
investigation. The cells often manifest a more immature elec-
trophysiological phenotype. While Ito1, IK1, and If are present
in hiPSC-CMs (Ma et al., 2011), their contribution to the bio-
physics of the cell has not been verified. The presence of INCX
has not been studied in detail but its functional presence can
also be presumed since intact calcium handling has been demon-
strated (Itzhaki et al., 2011; Lee et al., 2011). Currently, there
is no evidence for the functional presence or absence of IK,ACh.
The functional presence of sarcoplasmic reticulum (SR), ryan-
odine receptors (RyRs), and the calcium-binding protein CASQ2
has been demonstrated (Itzhaki et al., 2011; Lee et al., 2011;
Novak et al., 2012). However, due to the absence of t-tubulin
in hiPSC-CMs, the coupling between calcium influx through
L-type calcium channels and calcium release from the SR through
RyRs is significantly reduced. Therefore, the use of hiPSC-CMs to
study specific cardiac arrhythmia syndromes influenced by cal-
cium handling e.g., CPVT and LQT8, has to be focused on the
biophysical properties of the affected protein. Some of these issues
can be addressed by generating and assessing more refined popu-
lations of iPSCs in order to ensure that they have more consistent
electrophysiological profiles to faciliate mutant protein profiling
and testing of drugs.
Taking into account the technical limitations and current
caveats of utilizing iPSC technology, this approach has potential
value in the field of SADS on a number of fronts. First of all in the
case of an ion channel VUS, the behavior of that channel could
be assessed in the patients’ derived cardiomyocytes to assess the
extent to which it causes significant alterations in ion channel
function, trafficking and action potential duration. Furthermore,
in SADS victims or idiopathic VF survivors where no known dis-
ease causing mutation has been identified, the function of specific
ion channels and cellular electrophysiology could be interrogated
to identify novel causes of lethal arrhythmia and new drug tar-
gets. The specific problem of compound heterozygosity where
more than one VUS is inherited, which may only partially down-
regulate ion channel function/trafficking can also be evaluated in
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FIGURE 6 | Overview of the different strategies in the management of a
SADS family. Abbreviations include: EPS, electrophysiological study; Echo,
echocardiogram; CPEX, cardiopulmonary exercise testing; SAECG, signal
averaged ECG; NGS, next-generation sequencing.
the individual patient. Therefore, one can assess if this particular
combination of defects actually exerts important cellular electro-
physiological abnormalities, which are pro-arrhythmic and not
necessarily manifest on routine clinical testing. This informa-
tion could be utilized to prescribe prophylactic drug therapy and
protect against cardiac arrest in at-risk individuals. This con-
cept has recently been illustrated when hiPSCs were produced
from a healthy donor as well as from a mother and daughter,
wherein the mother was clinically asymptomatic with a moder-
ately prolonged QT interval and the daughter was symptomatic
with an excessively prolonged QT interval (arrhythmias, syncope,
and seizure episodes). Recording action potential durations from
the different hiPSC-cardiomyocytes showed that the clinical pro-
file was reflected in vitro (i.e., action potential longest in the
daughter’s cells, then the mother’s, then the healthy control) and
only hiPSC-cardiomyocytes produced from the daughter devel-
oped spontaneous arrhythmias (Terrenoire et al., 2013). The
next decade should help establish whether in vitro to in vivo
associations can be applied in other conditions with important
mechanistic and therapeutic implications in this and other arenas.
CONCLUSIONS
The diagnosis and management of SADS families is evolv-
ing rapidly (Figure 6 summarizes the current management
approaches). Comprehensive clinical assessment is still the main-
stay of screening families of SADS patients with highly specific
recommendations for complementing clinical assessment with
genetic screening options. Molecular autopsy adds another strat-
egy in the armory of screening of SADS families and validating
cases of SADS. However, with a limited understanding of the
etiology of the heritable arrhythmic syndromes, careful interpre-
tation of the added genetic information in the context of the
family being screened is critical. VUS are as yet not a viable
screening tool but provide a burgeoning data set to validate
through functional studies. Finally, the new techniques of full
exonic sequencing and iPSC technologies will certainly facilitate
diagnosis and management. However, the clinical relevance of
mutation screening and iPSC-derived information will need to
be carefully translated back to the individual relatives, in order
to ensure that any anomalies identified are clinically relevant and
impact on the patient’s well-being and arrhythmogenic risk.
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